Using sigma-ligands as part of a multi-receptor approach to target diseases of the brain

References

• Martin WR, Eades CG, Thompson J, et al. The effects of morphine-and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther. 1976;197(3):517–532.
   PubMed Web of Science ®Google Scholar
• Su T-P. Evidence for sigma opioid receptor: binding of [3H] SKF-10047 to etorphine-inaccessible sites in guinea-pig brain. J Pharmacol Exp Ther. 1982;223(2):284–290.
   PubMed Web of Science ®Google Scholar
• Vaupel DB. Naltrexone fails to antagonize the a effects of PCP and sskf 10,047 in the dog. Eur J Pharmacol. 1983;92:269–274.
   PubMed Web of Science ®Google Scholar
• Vignon J, Chicheportiche R, Chicheportiche M, et al. [3H] TCP: a new tool with high affinity for the PCP receptor in rat brain. Brain Res. 1983;280(1):194–197.
   PubMed Web of Science ®Google Scholar
• Wong EH, Kemp JA, Priestley T, et al. The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc Nat Acad Sci. 1986;83(18):7104–7108.
   PubMed Web of Science ®Google Scholar
• Su T-P, Wu XZ, Cone EJ, et al. Sigma compounds derived from phencyclidine: identification of PRE-084, a new, selective sigma ligand. J Pharmacol Exp Ther. 1991;259(2):543–550.
   PubMed Web of Science ®Google Scholar
• Hellewell SB, Bowen WD. A sigma-like binding site in rat pheochromocytoma (PC12) cells: decreased affinity for (+)-benzomorphans and lower molecular weight suggest a different sigma receptor form from that of guinea pig brain. Brain Res. 1990;527(2):244–253.
   PubMed Web of Science ®Google Scholar
• Quirion R, Bowen WD, Itzhak Y, et al. A proposal for the classification of sigma binding sites. Trends Pharmacol Sci. 1992;13:85–86.
   PubMed Web of Science ®Google Scholar
• Hanner M, Moebius FFFF, Flandorfer A, et al. Purification, molecular cloning and expression of the mammalian sigma1-binding site. Proc Nat Acad Sci. 1996;93(15):8072.
   PubMed Web of Science ®Google Scholar
• Kekuda R, Prasad PDPD, Fei Y-JY-J, et al. Cloning and functional expression of the human type 1 sigma receptor (hSigmaR1)*. Biochem Biophys Res Commun. 1996;229(2):553–558.
   PubMed Web of Science ®Google Scholar
• Seth P, Leibach FH, Ganapathy V. Cloning and structural analysis of the cDNA and the gene encoding the murine type 1 sigma receptor. Biochem Biophys Res Commun. 1997;241(2):535–540.
   PubMed Web of Science ®Google Scholar
• Schmidt HR, Zheng S, Gurpinar E, et al. Crystal structure of the human σ1 receptor. Nature. 2016;532:527.
   PubMed Web of Science ®Google Scholar
• Waterhouse A, Bertoni M, Bienert S, et al. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res. 2018;46(1):296–303.
   PubMed Web of Science ®Google Scholar
• Bertoni M, Kiefer F, Biasini M, et al. Modeling protein quaternary structure of homo-and hetero-oligomers beyond binary interactions by homology. Sci Rep. 2017;7(1):1–15.
   PubMedGoogle Scholar
• Mishra AK, Mavlyutov T, Singh DR, et al. The sigma-1 receptors are present in monomeric and oligomeric forms in living cells in the presence and absence of ligands. Biochem J. 2015;466:263–271.
   PubMed Web of Science ®Google Scholar
• Hong WC. Distinct regulation of σ1 receptor multimerization by its agonists and antagonists in transfected cells and rat liver membranes. J Pharmacol Exp Ther. 2020;373(2):290–301.
   PubMed Web of Science ®Google Scholar
• Gromek KA, Suchy FP, Meddaugh HR, et al. The oligomeric states of the purified sigma-1 receptor are stabilized by ligands. J Biol Chem. 2014;289(29):20333–20344.
   PubMed Web of Science ®Google Scholar
• Navarro G, Moreno E, Bonaventura J, et al. Cocaine inhibits dopamine D2 receptor signaling via sigma-1-D2 receptor heteromers. PloS One. 2013;8:4.
   Web of Science ®Google Scholar
• Aguinaga D, Medrano M, Vega-Quiroga I, et al. Cocaine effects on dopaminergic transmission depend on a balance between sigma-1 and sigma-2 receptor expression. Front Mol Neurosci. 2018;11:17.
   PubMed Web of Science ®Google Scholar
• Schmidt HR, Betz RM, Dror RO, et al. Structural basis for σ 1 receptor ligand recognition. Nat Struct Mol Biol. 2018;25(10):981.
   PubMed Web of Science ®Google Scholar
• Bermack JE, Debonnel G. The role of sigma receptors in depression. J Pharmacol Sci. 2005;336:317–336.
   Google Scholar
• Vilner BJ, de Costa BR, Bowen WD. Cytotoxic effects of sigma ligands: sigma receptor-mediated alterations in cellular morphology and viability. J Neurosci. 1995;15(1):117–134.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Su TP. The potential role of sigma-1 receptors in lipid transport and lipid raft reconstitution in the brain: implication for drug abuse. Life Sci. 2005;77(14):1612–1624.
   PubMed Web of Science ®Google Scholar
• Palmer CP, Mahen R, Schnell E, et al. Sigma-1 receptors bind cholesterol and remodel lipid rafts in breast cancer cell lines. Cancer Res. 2007;67(23):11166–11175.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Su TP. Intracellular dynamics of σ-1 receptors (σ1 binding sites) in NG108-15 cells. J Pharmacol Exp Ther. 2003;306(2):726–733.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER- mitochondrion interface regulate Ca 2 + signaling and cell survival. Cell. 2007;131(3):596–610.
   PubMed Web of Science ®Google Scholar
• Aydar E, Palmer CP, Klyachko VA, et al. The sigma receptor as a ligand-regulated auxiliary potassium channel subunit. Neuron. 2002;34(3):399–410.
   PubMed Web of Science ®Google Scholar
• Su TP, Hayashi T, Maurice T, et al. The sigma-1 receptor chaperone as an inter-organelle signaling modulator. Trends Pharmacol Sci. 2010;31(12):557–566.
   PubMed Web of Science ®Google Scholar
• Brimson J, Brown C, Safrany S. Antagonists show GTP-sensitive high affinity binding to the sigma-1 receptor. Br J Pharmacol. 2011;164:772–780.
   PubMed Web of Science ®Google Scholar
• Sánchez-blázquez P, Rodríguez-muñoz M, Herrero-labrador R. The calcium-sensitive Sigma-1 receptor prevents cannabinoids from provoking glutamate NMDA receptor hypofunction: implications in antinociception and psychotic diseases. Int J Neurosychopharmacol. 2014;17:1943–1955.
   PubMed Web of Science ®Google Scholar
• Vilner BJ, John CS, Bowen WD. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res. 1995;55(2):408–413.
   PubMed Web of Science ®Google Scholar
• Alon A, Schmidt HR, Wood MD, et al. Identification of the gene that codes for the σ2 receptor. Proc Nat Acad Sci. 2017.
   PubMed Web of Science ®Google Scholar
• de Costa BR, Bowen WD, Hellewell SB, et al. Synthesis and evaluation of optically pure [3H](+)pentazocine, a highly potent and selective radioligand for σ receptors. FEBS Lett. 1989;251(1–2):53–58.
   PubMed Web of Science ®Google Scholar
• Chu UB, Ruoho AE. Sigma receptor binding assays. Curr Protoc Pharmacol. 2015;71(1):1–34.
   PubMedGoogle Scholar
• Abbas H, Borde P, Willars GB, et al. Hazards of using masking protocols when performing ligand binding assays: lessons from the sigma-1 and sigma-2 receptors. Front Pharmacol. 2020;11:309.
   PubMed Web of Science ®Google Scholar
• Sonnenschein C, Olea N, Pasanen M, et al. Negative controls of cell proliferation: human prostate cancer cells and androgens. Cancer Res. 1989;49(13):3474–3481.
   PubMed Web of Science ®Google Scholar
• Ralph JL, M-C O-C, Lareyre -J-J, et al. Disruption of androgen regulation in the prostate by the environmental contaminant hexachlorobenzene. Environ Health Perspect. 2003;111(4):461–466.
   PubMed Web of Science ®Google Scholar
• Wetherill YB, Petre CE, Monk KR, et al. The xenoestrogen bisphenol a induces inappropriate androgen receptor activation and mitogenesis in prostatic adenocarcinoma cells 1 this work was supported by NIH training grant ES07250-13 (to YBW; environmental mutagenesis and Cancer) and NIH grant R01 CA93404-01 (to KEK). 1. Mol Cancer Ther. 2002;1(7):515–524.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Maurice T, Su T-P. Ca2+ signaling via sigma1-receptors: novel regulatory mechanism affecting intracellular Ca2+ concentration. J Pharmacol Exp Ther. 2000;293(3):788–798.
   PubMed Web of Science ®Google Scholar
• Brimson JM, Safrany ST, Qassam H, et al. Dipentylammonium binds to the sigma-1 receptor and protects against glutamate toxicity, attenuates dopamine toxicity and potentiates neurite outgrowth in various cultured cell lines. Neurotox Res. 2018;34(2):263–272.
   PubMed Web of Science ®Google Scholar
• Marrazzo A, Caraci F, Salinaro ET, et al. Neuroprotective effects of sigma-1 receptor agonists against beta-amyloid-induced toxicity. Neuroreport. 2005;16(11):1223–1226.
   PubMed Web of Science ®Google Scholar
• Francardo V, Bez F, Wieloch T, et al. Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism. Brain. 2014;137(7):1998–2014.
   PubMedGoogle Scholar
• Maurice T, Hiramatsu M, Itoh J, et al. Behavioral evidence for a modulating role of σ ligands in memory processes. I. Attenuation of dizocilpine (MK-801)-induced amnesia. Brain Res. 1994;647(1):44–56.
   PubMed Web of Science ®Google Scholar
• Maurice T, Lockhart BP. Neuroprotective and anti-amnesic potentials of sigma (σ) receptor ligands. Prog Neuro Psychopharmacol Biol Psychiatry. 1997;21(1):69–102.
   PubMed Web of Science ®Google Scholar
• Maurice T, Urani A, Phan V-L, et al. The interaction between neuroactive steroids and the σ1 receptor function: behavioral consequences and therapeutic opportunities. Brain Res Rev. 2001;37(1–3):116–132.
   PubMedGoogle Scholar
• Pande AC, Genève J, Scherrer B, et al. A placebo-controlled trial of igmesine in the treatment of major depression. Eur Neuropsychopharmacol. 1999;9:138.
   Web of Science ®Google Scholar
• Reilmann R, McGarry A, Grachev ID, et al. Safety and efficacy of pridopidine in patients with Huntington’s disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. Lancet Neurol. 2019;18(2):165–176.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Su TP. Regulating ankyrin dynamics: roles of sigma-1 receptors. Proc Natl Acad Sci U S A. 2001;98(2):491–496.
   PubMed Web of Science ®Google Scholar
• Watras J, Ehrlich BE. Bell-shaped calcium-response curves of lns (l, 4, 5) P 3-and calcium-gated channels from endoplasmic reticulum of cerebellum. Nature. 1991;351(6329):751–754.
   PubMed Web of Science ®Google Scholar
• Morphy R, Kay C, Rankovic Z. From magic bullets to designed multiple ligands. Drug Discov Today. 2004;9(15):641–651.
   PubMed Web of Science ®Google Scholar
• Frishman WH, Zuckerman AL. Amlodipine/atorvastatin: the first cross risk factor polypill for the prevention and treatment of cardiovascular disease. Expert Rev Cardiovasc Ther. 2004;2(5):675–681.
   PubMedGoogle Scholar
• Chung KF, Adcock IM. Combination therapy of long-acting β 2-adrenoceptor agonists and corticosteroids for asthma. Treat Respir Med. 2004;3(5):279–289.
   PubMedGoogle Scholar
• Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov. 2004;3(4):353–359.
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Frankenburg FR. Clozapine: a novel antipsychotic agent. N Engl J Med. 1991;324(11):746–754.
   PubMed Web of Science ®Google Scholar
• Bolognesi ML, Banzi R, Bartolini M, et al. Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer’s disease. J Med Chem. 2007;50(20):4882–4897.
   PubMed Web of Science ®Google Scholar
• Weinstock M, Bejar C, Wang R-H, et al. Advances in Research on Neurodegeneration. In: TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer’s disease. Vienna: Springer, 2000. 157–169.
   Google Scholar
• Sagi Y, Weinstock M, Youdim MB. Attenuation of MPTPinduced dopaminergic neurotoxicity by TV3326, a cholinesterasemonoamine oxidase inhibitor. J Neurochem. 2003;86(2):290–297.
   PubMed Web of Science ®Google Scholar
• Krieglstein J, Lippert K, Pöch G. Apparent independent action of nimodipine and glutamate antagonists to protect cultured neurons against glutamate-induced damage. Neuropharmacology. 1996;35(12):1737–1742.
   PubMed Web of Science ®Google Scholar
• Cassel JC, Jeltsch H. Serotonergic modulation of cholinergic function in the central nervous system: cognitive implications. Neuroscience. 1995;69(1):1–41.
   PubMed Web of Science ®Google Scholar
• Buccafusco JJ, Terry AV. Multiple central nervous system targets for eliciting beneficial effects on memory and cognition. J Pharmacol Exp Ther. 2000;295(2):438–446.
   PubMed Web of Science ®Google Scholar
• Ryskamp DA, Korban S, Zhemkov V, et al. Neuronal Sigma-1 receptors: signaling functions and protective roles in neurodegenerative diseases. Front Neurosci. 2019;13:862.
   PubMed Web of Science ®Google Scholar
• Pabba M, Wong AY, Ahlskog N, et al. NMDA receptors are upregulated and trafficked to the plasma membrane after sigma-1 receptor activation in the rat hippocampus. J Neurosci. 2014;34(34):11325–11338.
   PubMed Web of Science ®Google Scholar
• Kourrich S, Su T-P, Fujimoto M, et al. The sigma-1 receptor: roles in neuronal plasticity and disease. Trends Neurosci. 2012;35(12):1–10.
   PubMed Web of Science ®Google Scholar
• Pal A, Fontanilla D, Gopalakrishnan A, et al. The sigma-1 receptor protects against cellular oxidative stress and activates antioxidant response elements. Eur J Pharmacol. 2012;682(1–3):12–20.
   PubMed Web of Science ®Google Scholar
• Nishimura T, Ishima T, Iyo M, et al. Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signaling pathways. PLoS One. 2008;3(7):e2558–e2558.
   PubMed Web of Science ®Google Scholar
• Ishima T, Nishimura T, Iyo M, et al. Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by donepezil: role of sigma-1 receptors and IP3 receptors. Prog Neuro Psychopharmacol Biol Psychiatry. 2008;32(7):1656–1659.
   PubMed Web of Science ®Google Scholar
• Takebayashi M, Hayashi T, Su T-P. Nerve growth factor-induced neurite sprouting in PC12 cells involves ς-1 receptors: implications for antidepressants. J Pharmacol Exp Ther. 2002;303(3):1227–1237.
   PubMed Web of Science ®Google Scholar
• Terada K, Migita K, Matsushima Y, et al. Cholinesterase inhibitor rivastigmine enhances nerve growth factor-induced neurite outgrowth in PC12 cells via sigma-1 and sigma-2 receptors. PLoS ONE. 2018;13(12):1–16.
   Web of Science ®Google Scholar
• Oda T, Kume T, Katsuki H, et al. Donepezil potentiates nerve growth factor-induced neurite outgrowth in PC12 cells. J Pharmacol Sci. 2007;104(4):349–354.
   PubMed Web of Science ®Google Scholar
• Ishima T, Fujita Y, Hashimoto K. Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells. Eur J Pharmacol. 2014;727:167–173.
   PubMed Web of Science ®Google Scholar
• Ruscher K, Shamloo M, Rickhag M, et al. The sigma-1 receptor enhances brain plasticity and functional recovery after experimental stroke. Brain. 2011;134(3):732–746.
   PubMedGoogle Scholar
• Penas C, Pascual-Font A, Mancuso R, et al. Sigma receptor agonist 2-(4-morpholinethyl) 1 phenylcyclohexanecarboxylate (Pre084) increases GDNF and BiP expression and promotes neuroprotection after root avulsion injury. J Neurotrauma. 2011;28(5):831–840.
   PubMed Web of Science ®Google Scholar
• Segal R, Pomeroy S, Stiles C. Axonal growth and fasciculation linked to differential expression of BDNF and NT3 receptors in developing cerebellar granule cells. J Neurosci. 1995;15(7):4970–4981.
   PubMed Web of Science ®Google Scholar
• McGleenon B, Dynan K, Passmore A. Acetylcholinesterase inhibitors in Alzheimer’s disease. Br J Clin Pharmacol. 1999;48(4):471.
   PubMed Web of Science ®Google Scholar
• Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009;73(24):2061–2070.
   PubMed Web of Science ®Google Scholar
• Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370(4):322–333.
   PubMed Web of Science ®Google Scholar
• Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370(4):311–321.
   PubMed Web of Science ®Google Scholar
• Gundlach AL, Largent BL, Snyder SH. Autoradiographic localization of sigma receptor binding sites in guinea pig and rat central nervous system with (+) 3H-3-(3-hydroxyphenyl)-N-(1-propyl) piperidine. J Neurosci. 1986;6(6):1757–1770.
   PubMed Web of Science ®Google Scholar
• Kawamura K, Kubota K, Kobayashi T, et al. Evaluation of [11C]SA5845 and [11C]SA4503 for imaging of sigma receptors in tumors by animal PET. Ann Nucl Med. 2005;19(8):701–709.
   PubMed Web of Science ®Google Scholar
• Kawamura K, Kimura Y, Tsukada H, et al. An increase of sigma1 receptors in the aged monkey brain. Neurobiol Aging. 2003;24(5):745–752.
   PubMed Web of Science ®Google Scholar
• Mishina M, Ohyama M, Ishii K, et al. Low density of sigma 1 receptors in early Alzheimer’s disease. Ann Nucl Med. 2008;22(3):151.
   PubMed Web of Science ®Google Scholar
• Minoshima S, Giordani B, Berent S, et al. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol. 1997;42(1):85–94.
   PubMed Web of Science ®Google Scholar
• Lahmy V, Long R, Morin D, et al. Mitochondrial protection by the mixed muscarinic/σ1 ligand ANAVEX2-73, a tetrahydrofuran derivative, in Aβ25–35 peptide-injected mice, a nontransgenic Alzheimer’s disease model. Front Cell Neurosci. 2015;8:463.
   PubMed Web of Science ®Google Scholar
• Meunier J, Ieni J, Maurice T. The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor. Br J Pharmacol. 2006;149(8):998–1012.
   PubMed Web of Science ®Google Scholar
• Cacabelos R. Donepezil in Alzheimer’s disease: from conventional trials to pharmacogenetics. Neuropsychiatr Dis Treat. 2007;3(3):303–333.
   PubMedGoogle Scholar
• Maurice T. Protection by sigma-1 receptor agonists is synergic with donepezil, but not with memantine, in a mouse model of amyloid-induced memory impairments. Behav Brain Res. 2016;296:270–278.
   PubMed Web of Science ®Google Scholar
• Nguyen L, Lucke-Wold BP, Mookerjee SA, et al. Role of sigma-1 receptors in neurodegenerative diseases. J Pharmacol Sci. 2015;127(1):17–29.
   PubMed Web of Science ®Google Scholar
• Ablordeppey SY, Fischer JB, Glennon RA. Is a Nitrogen Atom an Important Pharmacophoric Element in Sigma Ligand Binding? Bioorg Med Chem. 2000;8:2105–2111.
   PubMed Web of Science ®Google Scholar
• Glennon RA, Ablordeppey SY, Ismaiel AM, et al. Structural Features Important for sigma1 Receptor Binding. J Med Chem. 1994;37(8):1214–1219.
   PubMed Web of Science ®Google Scholar
• Pascual R, Almansa C, Plata-Salamán C, et al. A new pharmacophore model for the design of sigma-1 ligands validated on a large experimental dataset. Front Pharmacol. 2019;10:519.
   PubMed Web of Science ®Google Scholar
• Yano T, Tanabe H, Kobayashi K, et al. Sigma-1 receptor is a molecular target for novel neuroprotectant T-817MA. Alzheimer’s Dementia. 2015;11(7):P861.
   Google Scholar
• Abe H, Jitsuki S, Nakajima W, et al. CRMP2-binding compound, edonerpic maleate, accelerates motor function recovery from brain damage. Science. 2018;360(6384):50–57.
   PubMed Web of Science ®Google Scholar
• Uehara T, Sumiyoshi T, Kurachi M. New pharmacotherapy targeting cognitive dysfunction of schizophrenia via modulation of GABA neuronal function. Curr Neuropharmacol. 2015;13(6):793–801.
   PubMed Web of Science ®Google Scholar
• Uehara T, Sumiyoshi T, Hattori H, et al. T-817MA, a novel neurotrophic agent, ameliorates loss of GABAergic parvalbumin-positive neurons and sensorimotor gating deficits in rats transiently exposed to MK-801 in the neonatal period. J Psychiatr Res. 2012;46(5):622–629.
   PubMed Web of Science ®Google Scholar
• Uehara T, Sumiyoshi T, Seo T, et al. T-817MA, but not Haloperidol and Risperidone, restores parvalbumin-positive γ-aminobutyric acid neurons in the prefrontal cortex and hippocampus of rats transiently exposed to MK-801 at the neonatal period. ISRN Psychiatry. 2012;2012:1–8. DOI:10.5402/2012/947149
   Google Scholar
• Takamura Y, Ono K, Matsumoto J, et al. Effects of the neurotrophic agent T-817MA on oligomeric amyloid-β–induced deficits in long-term potentiation in the hippocampal CA1 subfield. Neurobiol Aging. 2014;35(3):532–536.
   PubMed Web of Science ®Google Scholar
• Kimura T, Hong Nguyen PT, Ho SA, et al. T817MA, a neurotrophic agent, ameliorates the deficits in adult neurogenesis and spatial memory in rats infused icv with amyloidβ peptide. Br J Pharmacol. 2009;157(3):451–463.
   PubMed Web of Science ®Google Scholar
• Nguyen PTH, Kimura T, Ho SA, et al. Ameliorative effects of a neuroprotective agent, T817MA, on place learning deficits induced by continuous infusion of amyloidβ peptide (1–40) in rats. Hippocampus. 2007;17(6):443–455.
   PubMed Web of Science ®Google Scholar
• Moreno H, Choi S, Yu E, et al. Blocking effects of human tau on squid giant synapse transmission and its prevention by T-817 MA. Front Synaptic Neurosci. 2011;3:3.
   PubMedGoogle Scholar
• Fukushima T, Nakamura A, Iwakami N, et al. T-817MA, a neuroprotective agent, attenuates the motor and cognitive impairments associated with neuronal degeneration in P301L tau transgenic mice. Biochem Biophys Res Commun. 2011;407(4):730–734.
   PubMed Web of Science ®Google Scholar
• Schneider LS, Thomas RG, Hendrix S, et al. Safety and efficacy of edonerpic maleate for patients with mild to moderate alzheimer disease: a phase 2 randomized clinical trial. JAMA Neurol. 2019;76(11):1330–1339.
   PubMed Web of Science ®Google Scholar
• Schneider L, Porsteinsson A, Farlow M, et al. The neuroprotective and neurotrophic agent T-817MA for Alzheimer’s disease: randomized, double-blind, placebo-controlled proof-of-concept trial outcomes. Alzheimer’s Dementia. 2013;9(4):P530–P531.
   Google Scholar
• Sahlholm K, Sijbesma JWA, Maas B, et al. Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses. Psychopharmacology (Berl). 2015;232(18):3443–3453.
   PubMed Web of Science ®Google Scholar
• Johnston TH, Geva M, Steiner L, et al. Pridopidine, a clinicready compound, reduces 3, 4dihydroxyphenylalanineinduced dyskinesia in Parkinsonian macaques. Mov Disord. 2019;34(5):708–716.
   PubMed Web of Science ®Google Scholar
• Ryskamp D, Wu L, Wu J, et al. Pridopidine stabilizes mushroom spines in mouse models of Alzheimer’s disease by acting on the sigma-1 receptor. Neurobiol Dis. 2019;124:489–504.
   PubMed Web of Science ®Google Scholar
• Ryskamp D, Zhemkov V, Bezprozvanny I. Mutational analysis of sigma-1 receptor function in synaptic spines. Front Neurosci. 2019;13:1012.
   PubMed Web of Science ®Google Scholar
• Lahmy V, Meunier J, Malmström S, et al. Blockade of Tau hyperphosphorylation and Aβ 1–42 generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and σ 1 receptor agonist, in a nontransgenic mouse model of Alzheimer’s disease. Neuropsychopharmacology. 2013;38(9):1706.
   PubMed Web of Science ®Google Scholar
• Christ MG, Huesmann H, Nagel H, et al. Sigma-1 receptor activation induces autophagy and increases proteostasis capacity in vitro and in vivo. Cells. 2019;8(3):211.
   PubMed Web of Science ®Google Scholar
• Hall H, Iulita MF, Gubert P, et al. AF710B, an M1/sigma-1 receptor agonist with long-lasting disease-modifying properties in a transgenic rat model of Alzheimer’s disease. Alzheimer’s Dementia. 2018;14(6):811–823.
   PubMed Web of Science ®Google Scholar
• Neumeister KL, Riepe MW. Synergistic effects of antidementia drugs on spatial learning and recall in the APP23 transgenic mouse model of alzheimer’s disease. J Alzheimers Dis. 2012;30(2):245–251.
   PubMed Web of Science ®Google Scholar
• Wallace DR, Mactutus CF, Booze RM. Sigma binding sites identified by [3H] DTG are elevated in aged Fischer344× Brown Norway (F1) rats. Synapse. 2000;35(4):311–313.
   PubMed Web of Science ®Google Scholar
• Norbury R, Travis MJ, Erlandsson K, et al. In vivo imaging of muscarinic receptors in the aging female brain with (R, R)[123I]-I-QNB and single photon emission tomography. Exp Gerontol. 2005;40(3):137–145.
   PubMed Web of Science ®Google Scholar
• Inoue M, Suhara T, Sudo Y, et al. Age-related reduction of extrastriatal dopamine D2 receptor measured by PET. Life Sci. 2001;69(9):1079–1084.
   PubMed Web of Science ®Google Scholar
• Sheline YI, Mintun MA, Moerlein SM, et al. Greater loss of 5-HT2A receptors in midlife than in late life. Am J Psychiatry. 2002;159(3):430–435.
   PubMed Web of Science ®Google Scholar
• Meltzer CC, Smith G, Price JC, et al. Reduced binding of [18F] altanserin to serotonin type 2A receptors in aging: persistence of effect after partial volume correction. Brain Res. 1998;813(1):167–171.
   PubMed Web of Science ®Google Scholar
• Goldstein SR, Matsumoto RR, Thompson TL, et al. Motor effects of two sigma ligands mediated by nigrostriatal dopamine neurons. Synapse. 1989;4(3):254–258.
   PubMed Web of Science ®Google Scholar
• Gudelsky GA. Biphasic effect of sigma receptor ligands on the extracellular concentration of dopamine in the striatum of the rat. J Neural Transm. 1999;106(9–10):849–856.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Matsuno K, Murai M, et al. σ 1 receptor subtype is involved in the facilitation of cortical dopaminergic transmission in the rat brain. Neurochem Res. 1997;22(9):1105–1109.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Matsuno K, Mita S. Regional differences of the effect of σ receptor ligands on the acetylcholine release in the rat brain. J Neural Transm. 1996;103(6):661–669.
   PubMed Web of Science ®Google Scholar
• Matsuno K, Senda T, Kobayashi T, et al. Involvement of σ1 receptor in (+)-N-allylnormetazocine-stimulated hippocampal cholinergic functions in rats. Brain Res. 1995;690(2):200–206.
   PubMed Web of Science ®Google Scholar
• Ault DT, Werling LL. Differential modulation of NMDA-stimulated [3H] dopamine release from rat striatum by neuropeptide Y and σ receptor ligands. Brain Res. 1997;760(1–2):210–217.
   PubMed Web of Science ®Google Scholar
• Maurice T, Privat A. SA4503, a novel cognitive enhancer with σ1 receptor agonist properties, facilitates NMDA receptor-dependent learning in mice. Eur J Pharmacol. 1997;328(1):9–18.
   PubMed Web of Science ®Google Scholar
• Pedigo JNW. Neurotransmitter receptor plasticity in aging. Life Sci. 1994;55(25–26):1985–1991.
   PubMed Web of Science ®Google Scholar
• Monnet FP, Mahé V, Robel P, et al. Neurosteroids, via sigma receptors, modulate the [3H] norepinephrine release evoked by N-methyl-D-aspartate in the rat hippocampus. Proc Nat Acad Sci. 1995;92(9):3774–3778.
   PubMed Web of Science ®Google Scholar
• Fontanilla D, Johannessen M, Hajipour AR, et al. The hallucinogen N, N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science. 2009;323(5916):934–937.
   PubMed Web of Science ®Google Scholar
• Brailoiu E, Chakraborty S, Brailoiu GC, et al. Choline Is an Intracellular Messenger Linking Extracellular Stimuli to IP3-Evoked Ca2+ Signals through Sigma-1 Receptors. Cell Rep. 2019;26(2):330–337.
   PubMed Web of Science ®Google Scholar
• Labrie F, Bélanger A, Cusan L, et al. Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology. J Clin Endocrinol Metab. 1997;82(8):2403–2409.
   PubMed Web of Science ®Google Scholar
• Nafziger AN, Bowlin SJ, Jenkins PL, et al. Longitudinal changes in dehydroepiandrosterone concentrations in men and women. Transl Res. 1998;131(4):316–323.
   Google Scholar
• Orentreich N, Brind JL, Rizer RL, et al. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab. 1984;59(3):551–555.
   PubMed Web of Science ®Google Scholar
• Ravaglia G, Forti P, Maioli F, et al. The relationship of dehydroepiandrosterone sulfate (DHEAS) to endocrine-metabolic parameters and functional status in the oldest-old. Results from an Italian study on healthy free-living over-ninety-year-olds. J Clin Endocrinol Metab. 1996;81(3):1173–1178.
   PubMed Web of Science ®Google Scholar
• Cohen BM, Renshaw PF, Stoll AL, et al. Decreased brain choline uptake in older adults: an in vivo proton magnetic resonance spectroscopy study. Jama. 1995;274(11):902–907.
   PubMed Web of Science ®Google Scholar
• Cummings JL, Lyketsos CG, Peskind ER, et al. Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial. Jama. 2015;314(12):1242–1254.
   PubMed Web of Science ®Google Scholar
• Avanir. Avanir pharmaceuticals announces initiation of Phase III trial of AVP-786 for agitation in patients with Alzheimer’s disease. 2015.
   Google Scholar
• Peeters M, Romieu P, Maurice T, et al. Involvement of the sigma1 receptor in the modulation of dopaminergic transmission by amantadine. Eur J Neurosci. 2004;19(8):2212–2220.
   PubMed Web of Science ®Google Scholar
• Mishina M, Ishiwata K, Ishii K, et al. Function of sigma 1 receptors in Parkinson’s disease. Acta Neurol Scand. 2005;112(2):103–107.
   PubMed Web of Science ®Google Scholar
• Hong J, Wang L, Zhang T, et al. Sigma-1 receptor knockout increases α-synuclein aggregation and phosphorylation with loss of dopaminergic neurons in substantia nigra. Neurobiol Aging. 2017;59:171–183.
   PubMed Web of Science ®Google Scholar
• Mori T, Hayashi T, Su TP. Compromising σ-1 receptors at the endoplasmic reticulum render cytotoxicity to physiologically relevant concentrations of dopamine in a nuclear factor-κB/Bcl-2-dependent mechanism: potential relevance to Parkinson’s disease. J Pharmacol Exp Ther. 2012;341(3):663–671.
   PubMed Web of Science ®Google Scholar
• Francardo V, Geva M, Bez F, et al. Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson’s Disease. Neurotherapeutics. 2019;16(2):465–479.
   PubMed Web of Science ®Google Scholar
• AlSaif A, AlMohanna F, Bohlega S. A mutation in sigma1 receptor causes juvenile amyotrophic lateral sclerosis. Ann Neurol. 2011;70(6):913–919.
   PubMed Web of Science ®Google Scholar
• Watanabe S, Ilieva H, Tamada H, et al. Mitochondriaassociated membrane collapse is a common pathomechanism in SIGMAR 1and SOD 1linked ALS. EMBO Mol Med. 2016;8(12):1421–1437.
   PubMed Web of Science ®Google Scholar
• Almendra L, Laranjeira F, Fernández-Marmiesse A, et al. SIGMAR1 gene mutation causing Distal Hereditary Motor Neuropathy in a Portuguese family. Acta Myologica. 2018;37(1):2–4.
   PubMedGoogle Scholar
• FUS S Compound heterozygote mutations in the SIGMAR1 gene in an oldest-old patient with amyotrophic lateral sclerosis. 2018.
   Google Scholar
• Wong AY, Hristova E, Ahlskog N, et al. Aberrant subcellular dynamics of sigma-1 receptor mutants underlying neuromuscular diseases. Mol Pharmacol. 2016;90(3):238–253.
   PubMed Web of Science ®Google Scholar
• Dreser A, Vollrath JT, Sechi A, et al. The ALS-linked E102Q mutation in Sigma receptor-1 leads to ER stress-mediated defects in protein homeostasis and dysregulation of RNA-binding proteins. Cell Death Differ. 2017;24(10):1655–1671.
   PubMed Web of Science ®Google Scholar
• Prause J, Goswami A, Katona I, et al. Altered localization, abnormal modification and loss of function of Sigma receptor-1 in amyotrophic lateral sclerosis. Hum Mol Genet. 2013;22(8):1581–1600.
   PubMed Web of Science ®Google Scholar
• Mavlyutov TA, Epstein ML, Verbny YI, et al. Lack of sigma-1 receptor exacerbates ALS progression in mice. Neuroscience. 2013;240:129–134.
   PubMed Web of Science ®Google Scholar
• Mavlyutov TA, Epstein ML, Andersen KA, et al. The sigma-1 receptor is enriched in postsynaptic sites of C-terminals in mouse motoneurons. An anatomical and behavioral study. Neuroscience. 2010;167(2):247–255.
   PubMed Web of Science ®Google Scholar
• Martina M, Turcotte MEB, Halman S, et al. The sigma1 receptor modulates NMDA receptor synaptic transmission and plasticity via SK channels in rat hippocampus. J Physiol. 2007;578(1):143–157.
   PubMed Web of Science ®Google Scholar
• Balasuriya D, D’Sa L, Talker R, et al. A direct interaction between the sigma-1 receptor and the hERG voltage-gated K+ channel revealed by atomic force microscopy and homogeneous time-resolved fluorescence (HTRF®). J Biol Chem. 2014;289(46):32353–32363.
   PubMed Web of Science ®Google Scholar
• Mavlyutov TA, Guo L-W, Epstein ML, et al. Role of the sigma-1 receptor in amyotrophic lateral sclerosis (ALS). J Pharmacol Sci. 2015;127(1):10–16.
   PubMed Web of Science ®Google Scholar
• Peviani M, Salvaneschi E, Bontempi L, et al. Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation. Neurobiol Dis. 2014;62:218–232.
   PubMed Web of Science ®Google Scholar
• Ionescu A, Gradus T, Altman T, et al. Targeting the sigma-1 receptor via pridopidine ameliorates central features of ALS pathology in a SOD1G93A model. Cell Death Dis. 2019;10:3.
   Web of Science ®Google Scholar
• Ishima T, Hashimoto K. Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by ifenprodil: the role of sigma-1 and IP3 receptors. PloS One. 2012;7(5):e37989–e37989.
   PubMed Web of Science ®Google Scholar
• Guzmán-Lenis MS, Navarro X, Casas C. Selective sigma receptor agonist 2-(4-morpholinethyl) 1-phenylcyclohexanecarboxylate (PRE084) promotes neuroprotection and neurite elongation through protein kinase C (PKC) signaling on motoneurons. Neuroscience. 2009;162(1):31–38.
   PubMed Web of Science ®Google Scholar
• Taylor CP, Traynelis SF, Siffert J, et al. Pharmacology of dextromethorphan: relevance to dextromethorphan/quinidine (Nuedexta®) clinical use. Pharmacol Ther. 2016;164:170–182.
   PubMed Web of Science ®Google Scholar
• de Lera Ruiz M, Kraus RL. Voltage-gated sodium channels: structure, function, pharmacology, and clinical indications. J Med Chem. 2015;58(18):7093–7118.
   PubMed Web of Science ®Google Scholar
• Smith R, Pioro E, Myers K, et al. Enhanced bulbar function in amyotrophic lateral sclerosis: the Nuedexta treatment trial. Neurotherapeutics. 2017;14(3):762–772.
   PubMed Web of Science ®Google Scholar
• Brooks BR, Crumpacker D, Fellus J, et al. PRISM: a novel research tool to assess the prevalence of pseudobulbar affect symptoms across neurological conditions. PLoS One. 2013;8:8.
   Web of Science ®Google Scholar
• Thakore NJ, Pioro EP. Laughter, crying and sadness in ALS. J Neurol Neurosurg Psychiatry. 2017;88(10):825–831.
   PubMed Web of Science ®Google Scholar
• Pioro EP, Brooks BR, Cummings J, et al. Dextromethorphan plus ultra LowDose quinidine reduces pseudobulbar affect. Ann Neurol. 2010;68(5):693–702.
   PubMed Web of Science ®Google Scholar
• McLean S, Weber E. Autoradiographic visualization of haloperidol-sensitive sigma receptors in guinea-pig brain. Neuroscience. 1988;25(1):259–269.
   PubMed Web of Science ®Google Scholar
• Tortella FC, Pellicano M, Bowery NG. Dextromethorphan and neuromodulation: old drug coughs up new activities. Trends Pharmacol Sci. 1989;10(12):501–507.
   PubMed Web of Science ®Google Scholar
• Musacchio J, Klein M, Canoll PD. Dextromethorphan and sigma ligands: common sites but diverse effects. Life Sci. 1989;45(19):1721–1732.
   PubMed Web of Science ®Google Scholar
• Compston A, Coles A. Multiple sclerosis.[Published erratum appears in 2002 Lancet 360: 648.]. Lancet. 2002;359:1221–1231.
   PubMed Web of Science ®Google Scholar
• Rajda C, Pukoli D, Bende Z, et al. Excitotoxins, mitochondrial and redox disturbances in multiple sclerosis. Int J Mol Sci. 2017;18(2):353.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Su T-P. Sigma-1 receptors at galactosylceramide-enriched lipid microdomains regulate oligodendrocyte differentiation. Proc Nat Acad Sci. 2004;101(41):14949–14954.
   PubMed Web of Science ®Google Scholar
• Demerens C, Stankoff B, Zalc B, et al. Eliprodil stimulates CNS myelination: new prospects for multiple sclerosis? Neurology. 1999;52(2):346.
   PubMed Web of Science ®Google Scholar
• Lisak RP, Nedelkoska L, Benjamins JA. Effects of dextromethorphan on glial cell function: proliferation, maturation, and protection from cytotoxic molecules. Glia. 2014;62(5):751–762.
   PubMed Web of Science ®Google Scholar
• Oxombre B, LeeChang C, Duhamel A, et al. Highaffinity σ1 protein agonist reduces clinical and pathological signs of experimental autoimmune encephalomyelitis. Br J Pharmacol. 2015;172(7):1769–1782.
   PubMed Web of Science ®Google Scholar
• Schaffar G, Breuer P, Boteva R, et al. Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation. Mol Cell. 2004;15(1):95–105.
   PubMed Web of Science ®Google Scholar
• Martinez-Vicente M, Talloczy Z, Wong E, et al. Cargo recognition failure is responsible for inefficient autophagy in Huntington’s disease. Nat Neurosci. 2010;13(5):567.
   PubMed Web of Science ®Google Scholar
• Mochel F, Haller RG. Energy deficit in Huntington disease: why it matters. J Clin Invest. 2011;121(2):493–499.
   PubMed Web of Science ®Google Scholar
• Miki Y, Tanji K, Mori F, et al. Sigma-1 receptor is involved in degradation of intranuclear inclusions in a cellular model of Huntington’s disease. Neurobiol Dis. 2015;74:25–31.
   PubMed Web of Science ®Google Scholar
• Hyrskyluoto A, Pulli I, Törnqvist K, et al. Sigma-1 receptor agonist PRE084 is protective against mutant huntingtin-induced cell degeneration: involvement of calpastatin and the NF-κ B pathway. Cell Death Dis. 2013;4(5):e646–e646.
   PubMedGoogle Scholar
• Ryskamp D, Wu J, Geva M, et al. The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease. Neurobiol Dis. 2017;97:46–59.
   PubMed Web of Science ®Google Scholar
• Garcia-Miralles M, Geva M, Tan JY, et al. Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice. JCI Insight. 2017;2:23.
   Web of Science ®Google Scholar
• Nguyen KQ, Rymar VV, Sadikot AF. Impaired TrkB signaling underlies reduced BDNF-mediated trophic support of striatal neurons in the R6/2 mouse model of Huntington’s disease. Front Cell Neurosci. 2016;10:37.
   PubMed Web of Science ®Google Scholar
• Kusko R, Dreymann J, Ross J, et al. Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse. Mol Neurodegener. 2018;13(1):25.
   PubMedGoogle Scholar
• Xie Y, Hayden MR, Xu B. BDNF overexpression in the forebrain rescues Huntington’s disease phenotypes in YAC128 mice. J Neurosci. 2010;30(44):14708–14718.
   PubMed Web of Science ®Google Scholar
• Kikuchi-Utsumi K, Nakaki T. Chronic treatment with a selective ligand for the sigma-1 receptor chaperone, SA4503, up-regulates BDNF protein levels in the rat hippocampus. Neurosci Lett. 2008;440(1):19–22.
   PubMed Web of Science ®Google Scholar
• Yagasaki Y, Numakawa T, Kumamaru E, et al. Chronic antidepressants potentiate via sigma-1 receptors the brain-derived neurotrophic factor-induced signaling for glutamate release. J Biol Chem. 2006;281(18):12941–12949.
   PubMed Web of Science ®Google Scholar
• Fujimoto M, Hayashi T, Urfer R, et al. Sigma1 receptor chaperones regulate the secretion of brainderived neurotrophic factor. Synapse. 2012;66(7):630–639.
   PubMed Web of Science ®Google Scholar
• Geva M, Kusko R, Soares H, et al. Pridopidine activates neuroprotective pathways impaired in Huntington Disease. Hum Mol Genet. 2016;25(18):3975–3987.
   PubMed Web of Science ®Google Scholar
• Investigators HSGH. A randomized, doubleblind, placebocontrolled trial of pridopidine in Huntington’s disease. Mov Disord. 2013;28(10):1407–1415.
   PubMed Web of Science ®Google Scholar
• De Yebenes JG, Landwehrmeyer B, Squitieri F, et al. Pridopidine for the treatment of motor function in patients with Huntington’s disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2011;10(12):1049–1057.
   PubMed Web of Science ®Google Scholar
• McGarry A, Auinger P, Kieburtz K, et al. Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington Disease. J Huntington’s Dis. 2020;9(2):173–184.
   PubMed Web of Science ®Google Scholar
• Nestler EJ, Barrot M, DiLeone RJ, et al. Neurobiology of depression. Neuron. 2002 Mar 28;34(1):13–25.
   PubMed Web of Science ®Google Scholar
• Stahl SM. Antidepressant treatment of psychotic major depression: potential role of the σ receptor. CNS Spectr. 2005;10(4):319–323.
   PubMed Web of Science ®Google Scholar
• Hyman SE, Nestler EJ. Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am J Psychiatry. 1996;153(2):151.
   PubMed Web of Science ®Google Scholar
• Itzhak Y. Multiple Affinity Binding States of the a Receptor: agents Effect of GTP-Binding Protein-modifying agents. Mol Pharmacol. 1989;36(4):512–517.
   PubMed Web of Science ®Google Scholar
• Narita N, Hashimoto K, Tomitaka S, et al. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol. 1996;307(1):117–119.
   PubMed Web of Science ®Google Scholar
• Shirayama Y, Nishikawa T, Umino A, et al. p-Chlorophenylalanine-reversible reduction of σ binding sites by chronic imipramine treatment in rat brain. Eur J Pharmacol. 1993;237(1):117–126.
   PubMed Web of Science ®Google Scholar
• Urani A, Romieu P, Roman FJ, et al. Enhanced antidepressant efficacy of sigma1 receptor agonists in rats after chronic intracerebroventricular infusion of beta-amyloid-(1-40) protein. Eur J Pharmacol. 2004;486(2):151–161.
   PubMed Web of Science ®Google Scholar
• Matsuno K, Kobayashi T, Tanaka MK, et al. σ1 Receptor subtype is involved in the relief of behavioral despair in the mouse forced swimming test. Eur J Pharmacol. 1996;312(3):267–271.
   PubMed Web of Science ®Google Scholar
• Urani A, Roman FJ, Phan V-L, et al. The Antidepressant-Like Effect Induced by ς1-Receptor Agonists and Neuroactive Steroids in Mice Submitted to the Forced Swimming Test. J Pharmacol Exp Ther. 2001;298(3):1269–1279.
   PubMed Web of Science ®Google Scholar
• Ukai M, Maeda H, Nanya Y, et al. Beneficial effects of acute and repeated administrations of sigma receptor agonists on behavioral despair in mice exposed to tail suspension. Pharmacol Biochem Behav. 1998;61(3):247–252.
   PubMed Web of Science ®Google Scholar
• Sabino V, Cottone P, Parylak SL, et al. Sigma-1 receptor knockout mice display a depressive-like phenotype. Behav Brain Res. 2009;198(2):472–476.
   PubMed Web of Science ®Google Scholar
• Itzhak Y, Kassim CO. Clorgyline displays high affinity for sigma binding sites in C57BL/6 mouse brain. Eur J Pharmacol. 1990;176(1):107.
   PubMed Web of Science ®Google Scholar
• Kulkarni SK, Dhir A. On the mechanism of antidepressant-like action of berberine chloride. Eur J Pharmacol. 2008;589(1–3):163–172.
   PubMed Web of Science ®Google Scholar
• Wang J, Mack AL, Coop A, et al. Novel sigma (sigma) receptor agonists produce antidepressant-like effects in mice. Eur Neuropsychopharmacol. 2007;17(11):708–716.
   PubMed Web of Science ®Google Scholar
• Brimson JM, Akula KK, Abbas H, et al. Simple ammonium salts acting on sigma-1 receptors yield potential treatments for cancer and depression. Sci Rep. 2020;10(1):9251.
   PubMed Web of Science ®Google Scholar
• Bermack JE, Debonnel G. Modulation of serotonergic neurotransmission by shortand longterm treatments with sigma ligands. Br J Pharmacol. 2001;134(3):691–699.
   PubMed Web of Science ®Google Scholar
• Roman FJ, Pascaud X, Martin B, et al. JO 1784, a potent and selective ligand for rat and mouse brain σsites. J Pharm Pharmacol. 1990;42(6):439–440.
   PubMed Web of Science ®Google Scholar
• Müller WE, Siebert B, Holoubek G, et al. Neuropharmacology of the anxiolytic drug opripramol, a sigma site ligand. Pharmacopsychiatry. 2004;37(S 3):189–197.
   PubMedGoogle Scholar
• Volz HP, Stoll KD. Clinical trials with sigma ligands. Pharmacopsychiatry. 2004;37(S 3):214–220.
   Google Scholar
• Urani A, Romieu P, Portales-Casamar E, et al. The antidepressant-like effect induced by the sigma 1 (σ 1) receptor agonist igmesine involves modulation of intracellular calcium mobilization. Psychopharmacology (Berl). 2002;163(1):26–35.
   PubMed Web of Science ®Google Scholar
• Dhir A, Kulkarni SK. Involvement of sigma-1 receptor modulation in the antidepressant action of venlafaxine. Neurosci Lett. 2007;420(3):204–208.
   PubMed Web of Science ®Google Scholar
• Schatzberg AF. New approaches to managing psychotic depression. J Clin Psychiatry. 2003;64(1):19–23.
   PubMedGoogle Scholar
• Gatti F, Bellini L, Gasperini M, et al. Fluvoxamine alone in the treatment of delusional depression. Am J Psychiatry. 1996;153(3):414.
   PubMed Web of Science ®Google Scholar
• Hirschfeld RMA. Efficacy of SSRIs and newer antidepressants in severe depression: comparison with TCAs. J Clin Psychiatry. 1999;60(5):326–335.
   PubMed Web of Science ®Google Scholar
• Zanardi R, Franchini L, Gasperini M, et al. Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: a controlled study. J Clin Psychopharmacol. 1998;18(6):441–446.
   PubMed Web of Science ®Google Scholar
• Zanardi R, Franchini L, Gasperini M, et al. Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. Am J Psychiatry. 1996;153(12):1631.
   PubMed Web of Science ®Google Scholar
• Hindmarch I, Hashimoto K. Cognition and depression: the effects of fluvoxamine, a sigma1 receptor agonist, reconsidered. Psychopharmacology. 2010;25(3):193–200.
   PubMed Web of Science ®Google Scholar
• Yoshida H. ER stress and diseases. Febs J. 2007;274(3):630–658.
   PubMed Web of Science ®Google Scholar
• Hoozemans JJM, Veerhuis R, Van Haastert ES, et al. The unfolded protein response is activated in Alzheimer’s disease. Acta Neuropathol. 2005;110(2):165–172.
   PubMed Web of Science ®Google Scholar
• Katayama T, Imaizumi K, Manabe T, et al. Induction of neuronal death by ER stress in Alzheimer’s disease. J Chem Neuroanat. 2004;28(1–2):67–78.
   PubMed Web of Science ®Google Scholar
• Unterberger U, Höftberger R, Gelpi E, et al. Endoplasmic reticulum stress features are prominent in Alzheimer disease but not in prion diseases in vivo. J Neuropathol Exp Neurol. 2006;65(4):348–357.
   PubMed Web of Science ®Google Scholar
• Kakiuchi C, Ishiwata M, Kametani M, et al. Quantitative analysis of mitochondrial DNA deletions in the brains of patients with bipolar disorder and schizophrenia. Int J Neuropsychopharmacol. 2005;8(4):515–522.
   PubMed Web of Science ®Google Scholar
• Czéh B, Simon M, Schmelting B, et al. Astroglial plasticity in the hippocampus is affected by chronic psychosocial stress and concomitant fluoxetine treatment. Neuropsychopharmacology. 2006;31(8):1616.
   PubMed Web of Science ®Google Scholar
• Hajszan T, MacLusky NJ, Leranth C. Shortterm treatment with the antidepressant fluoxetine triggers pyramidal dendritic spine synapse formation in rat hippocampus. Eur J Neurosci. 2005;21(5):1299–1303.
   PubMed Web of Science ®Google Scholar
• Kodama M, Fujioka T, Duman RS. Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol Psychiatry. 2004;56(8):570–580.
   PubMed Web of Science ®Google Scholar
• Malberg JE, Duman RS. Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. Neuropsychopharmacology. 2003;28(9):1562.
   PubMed Web of Science ®Google Scholar
• Tsai SY, Hayashi T, Harvey BK, et al. Sigma-1 receptors regulate hippocampal dendritic spine formation via a free radical-sensitive mechanism involving Rac1•GTP pathway. Proc Nat Acad Sci. 2009;106(52):1–6.
   Web of Science ®Google Scholar
• Molteni R, Calabrese F, Bedogni F, et al. Chronic treatment with fluoxetine up-regulates cellular BDNF mRNA expression in rat dopaminergic regions. Int J Neuropsychopharmacol. 2006;9(3):307–317.
   PubMed Web of Science ®Google Scholar
• Russo-Neustadt AA, Alejandre H, Garcia C, et al. Hippocampal brain-derived neurotrophic factor expression following treatment with reboxetine, citalopram, and physical exercise. Neuropsychopharmacology. 2004;29(12):2189–2199.
   PubMed Web of Science ®Google Scholar
• Huang EJ, Reichardt LF. Trk receptors: roles in neuronal signal transduction. Annu Rev Biochem. 2003;72(1):609–642.
   PubMed Web of Science ®Google Scholar
• Ito K, Hirooka Y, Matsukawa R, et al. Decreased brain sigma-1 receptor contributes to the relationship between heart failure and depression. Cardiovasc Res. 2012;93(1):33–40.
   PubMed Web of Science ®Google Scholar
• Stahl SM, Pradko JF, Haight BR, et al. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry. 2004;6(4):159.
   PubMedGoogle Scholar
• Dhir A, Kulkarni S. Possible involvement of sigma1 receptors in the antiimmobility action of bupropion, a dopamine reuptake inhibitor. Fundam Clin Pharmacol. 2008;22(4):387–394.
   PubMed Web of Science ®Google Scholar
• Anderson A, Iosifescu DV, Jacobson M, et al. Efficacy and safety of AXS-05, an oral NMDA receptor antagonist with multimodal activity, in major depressive disorder: results of a phase 2, double-blind, active-controlled trial. W43. ASCP Annual Meeting; 2019 May 18–22. San Francisco, CA.
   Google Scholar
• Matsumoto RR. σ Receptors: historical perspective and background. Boston, MA: Springer; 2007. p. 1–23.
   Google Scholar
• Gebreselassie D, Bowen WD. Sigma-2 receptors are specifically localized to lipid rafts in rat liver membranes. Eur J Pharmacol. 2004;493(1–3):19–28.
   PubMed Web of Science ®Google Scholar
• Zeng C, Vangveravong S, Xu J, et al. Subcellular localization of sigma-2 receptors in breast cancer cells using two-photon and confocal microscopy. Cancer Res. 2007;67(14):6708–6716.
   PubMed Web of Science ®Google Scholar
• Xu J, Zeng C, Chu W, et al. Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site. Nat Commun. 2011;2:380.
   PubMed Web of Science ®Google Scholar
• Vilner BJ, Bowen WD. Modulation of cellular calcium by sigma-2 receptors: release from intracellular stores in human SK-N-SH neuroblastoma cells. J Pharmacol Exp Ther. 2000;292(3):900–911.
   PubMed Web of Science ®Google Scholar
• Wilke RA, Mehta RP, Lupardus PJ, et al. Sigma receptor photolabeling and sigma receptor-mediated modulation of potassium channels in tumor cells. J Biol Chem. 1999;274(26):18387–18392.
   PubMed Web of Science ®Google Scholar
• Leitner ML, Hohmann AG, Patrick SL, et al. Regional variation in the ratio of σ1 to σ2 binding in rat brain. Eur J Pharmacol. 1994;259(1):65–69.
   PubMed Web of Science ®Google Scholar
• Hellewell SB, Bruce A, Feinstein G, et al. Rat liver and kidney contain high densities of σ1 and σ2 receptors: characterization by ligand binding and photoaffinity labeling. Eur J Pharmacol. 1994;268(1):9–18.
   PubMed Web of Science ®Google Scholar
• Geldenhuys WJ, Van der Schyf CJ. Designing drugs with multi-target activity: the next step in the treatment of neurodegenerative disorders. Expert Opin Drug Discov. 2013;8(2):115–129.
   PubMed Web of Science ®Google Scholar
• Zeng C, Rothfuss JM, Zhang J, et al. Functional assays to define agonists and antagonists of the sigma-2 receptor. Anal Biochem. 2014;448:68–74.
   PubMed Web of Science ®Google Scholar
• Johannessen M, Fontanilla D, Mavlyutov T, et al. Antagonist action of progesterone at σ-receptors in the modulation of voltage-gated sodium channels. Am J Physiol Cell Physiol. 2011;300(2):C328–C337.
   PubMed Web of Science ®Google Scholar
• Riad A, Zeng C, Weng -C-C, et al. Sigma-2 Receptor/TMEM97 and PGRMC-1 Increase the Rate of Internalization of LDL by LDL Receptor through the Formation of a Ternary Complex. Sci Rep. 2018;8(1):16845.
   PubMedGoogle Scholar
• Izzo NJ, Xu J, Zeng C, et al. Alzheimer’s therapeutics targeting amyloid beta 1–42 oligomers II: sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity. PloS One. 2014;9(11):e111899–e111899.
   PubMed Web of Science ®Google Scholar
• Yi B, Sahn JJ, Ardestani PM, et al. Small molecule modulator of sigma 2 receptor is neuroprotective and reduces cognitive deficits and neuroinflammation in experimental models of Alzheimer’s disease. J Neurochem. 2017;140(4):561–575.
   PubMed Web of Science ®Google Scholar
• Blass BE, Rogers JP. The sigma-2 (σ-2) receptor: a review of recent patent applications: 2013–2018. Expert Opin Ther Pat. 2018;28(9):655–663.
   PubMed Web of Science ®Google Scholar
• Sanchez C, Arnt J, Costall B, et al. The selective ς2-Ligand Lu 28-179 has potent anxiolytic-like effects in Rodents. J Pharmacol Exp Ther. 1997;283(3):1323–1332.
   PubMed Web of Science ®Google Scholar
• Sanchez C, Papp M. The selective σ2 ligand Lu 28-179 has an antidepressant-like profile in the rat chronic mild stress model of depression. Behav Pharmacol. 2000;11(2):117–124.
   PubMed Web of Science ®Google Scholar
• Zerkak D, Dougados M. Benefit/risk of combination therapies. Clin Exp Rheumatol. 2004;22:S71–S71.
   PubMed Web of Science ®Google Scholar
• Steele LS, Glazier RH. Is donepezil effective for treating Alzheimer’s disease? Can Family Physician. 1999;45:917.
   PubMed Web of Science ®Google Scholar
• Adams DR, Kern DW, Wroblewski KE, et al. Olfactory dysfunction predicts subsequent dementia in older US adults. J Am Geriatr Soc. 2018;66(1):140–144.
   PubMed Web of Science ®Google Scholar
• Pinto JM, Wroblewski KE, Kern DW, et al. Olfactory dysfunction predicts 5-year mortality in older adults. PloS One. 2014;9(10):e107541–e107541.
   PubMed Web of Science ®Google Scholar
• Hudd F, Shiel A, Harris M, et al. Novel blood biomarkers that correlate with cognitive performance and hippocampal volumetry: potential for early diagnosis of Alzheimer’s disease. J Alzheimers Dis. 2019;67(3):1–17.
   Web of Science ®Google Scholar